Phase 3 Kidney Cancer Trial, Recruiting NCT07489495 Sponsor: Merck Sharp & Dohme LLC Condition: Kidney Cancer
Back to Kidney Cancer

Phase 3 Kidney Cancer Trial, Recruiting

NCT07489495
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with advanced kidney cancer (specifically a type called clear cell renal cell carcinoma) that cannot be removed by surgery, and it has spread to other parts of the body (Stage IV)
  • Your cancer can be measured using scans, meaning there are visible tumors that doctors can track
  • You have received no more than 3 previous drug treatments for your kidney cancer, and only one of those treatments was a type of immunotherapy known as a "checkpoint inhibitor" (such as pembrolizumab or nivolumab)

Who may not be able to join:

  • Your blood oxygen level is below 92% while resting, or you currently need or have needed extra oxygen on a regular basis
  • You have had a significant heart condition or problem in the last 12 months before starting the trial
  • You have had a blood clot in a deep vein (such as in your leg) in the past 3 months, unless it is stable, not causing symptoms, and you have been on blood-thinning medication for at least 4 weeks
  • Your heart is not pumping blood efficiently enough, based on a specific heart function measurement (confirm with trial site)
  • You have had major surgery within the last 8 weeks before joining the trial
  • You currently have inflammation or scarring of the lungs (pneumonitis or interstitial lung disease)
  • You have a history of HIV infection
  • You have a current Hepatitis B or Hepatitis C infection
  • You have another cancer that is still growing or has required active treatment within the past 3 years
  • You have previously had an organ transplant (such as a kidney, liver, or heart transplant)
  • You have not fully recovered from a major surgery, or you are still experiencing complications from a surgery

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Medical Director, Merck Sharp & Dohme LLC

Phone: 1-888-577-8839

Australian sites

Macquarie University ( Site 2700), Macquarie University, New South Wales

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
9 April 2026
Est. completion
27 November 2030

Where this trial is recruiting

🇦🇷 Argentina 🇦🇺 Australia 🇧🇷 Brazil 🇨🇿 Czechia 🇩🇰 Denmark 🇫🇷 France 🇬🇷 Greece 🇮🇱 Israel 🇮🇹 Italy 🇳🇱 Netherlands 🇵🇱 Poland 🇰🇷 South Korea 🇪🇸 Spain Turkey (Türkiye)

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Progression-free Survival (PFS); Overall Survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov